Malignant GliomasPhase 2NCT00463073
Cetuximab, Bevacizumab and Irinotecan for Patients With Malignant Glioblastomas
A Phase 2 study testing Cetuximab, Bevacizumab and Irinotecan in people with Malignant Gliomas, run by Copenhagen University Hospital, Rigshospitalet at 3 sites in Denmark.
Trial summary
Irinotecan has demonstrated activity in malignant gliomas in multiple phase II studies. The activity is limited, with an approximately 15 % response rate and a progression-free survival of 3-5 months. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Malignant Gliomas
- What is being tested?
- Cetuximab, Bevacizumab and Irinotecan
- How many people
- 32 participants
- Where
- 3 sitesDenmark
- Study dates
- Aug 2006to Dec 2008
- Phase
- Phase 2
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Written informed consent
- Histological verification of primary GBM
- Recurrence or progression after standard treatment (debulking surgery of possible, radiotherapy and temozolamide within last six months)
- Evidence of measurable recurrent progressive primary GBM (CT/MRI scan)
- PS 0-2 (ECOG scale)
- Age > 18
Show all 20Show fewer
- Life expectancy > 3 month
- Normal organ function:
- Platelets > 125 x 109/l
- Hemoglobin >6,2 mmol/l
- Leukocytes > 3 x 109/l
- ACN> 1,5 x 109/l
- ASAT and/or ALAT < 3 x upper normal limit
- Bilirubin < 1,5 x upper normal limit
- Creatinine clearance > 45 ml/min
- Creatinine < 1,5 x upper normal limit
- APTT < normal limit
- INR < normal limit
- Cholesterol < 7 mmol/l
- Fertile females must use oral contraceptive, IUD (intrauterine device) or preservatives. Fertile males must use preservatives.
Who cannot join
- Radiotherapy or chemotherapy within the last 4 weeks.
- Co-medication that may interfere with study results; e.g. immunosuppressive agents other than corticosteroids
- Prior EGFR- or VEGFR- based therapy.
- Any condition (medical, social, psychological), which would prevent adequate information and follow-up
- Any other active malignancy or previous malignancies within the last 5 years, except, adequately treated basal or squamous cell carcinoma of the skin, or carcinoma in situ.
- No hypercholesterolemia or hypertriglyceridemia (despite lipid-lowering therapy).
Show all 18Show fewer
- Any significant cardiac disease (New York Heart Association Class II or greater), arrhythmia, congestive heart failure, acute myocardial infarction within 6 months or unstable angina pectoris.
- Clinically significant peripheral vascular disease
- Evidence of bleeding diathesis, coagulapathy or taking ASA, NSAIDs or clopidogrel
- Major surgical procedure, open biopsy, or significant traumatic injury within 28 days prior to day 0, anticipation of need for major surgical procedure during the curse of the study
- Minor surgical procedures, fine needle aspirations or core biopsies within 7 days prior to day 0
- History of abdominal fistula, gastrointestinal perforation or intra-abdominal abscess within 6 month prior to day 0
- History of known HIV, Hepatitis B and Hepatitis C negative
- Any ongoing infection, uncontrolled diabetes mellitus, serious non-healing wound, ulcer or bone fracture
- Pregnancy or breast feeding
- Requires therapeutic anti-coagulation
- Blood pressure > 150/100 mmHG
- Grade 2 or greater proteinuria
Trial locations and contacts
3 sites in 1 country.
Denmark3 sites
Aalborg University Hospital
Aalborg, 9000
Rigshospitalet
Copenhagen, 2100
Odense University Hospital
Odense, 5000
About this study
Official title: A Phase II Trial With Cetuximab, Bevacizumab and Irinotecan for Patients With Malignant Glioblastomas and Progression After Radiation Therapy and Temozolamide
Irinotecan has demonstrated activity in malignant gliomas in multiple phase II studies. The activity is limited, with an approximately 15 % response rate and a progression-free survival of 3-5 months. Given the synergy between irinotecan and bevacizumab in colorectal cancer, and the high-level expression of vascular endothelial growth factor on malignant gliomas, one would expect synergy between bevacizumab and irinotecan against gliomas. In addition, 40-50 % of GBM have EGFR amplification/mutation making the EGFR an additional target. By combing cetuximab, with irinotecan and bevacizumab, one would expect further response, than irinotecan and bevacizumab alone. In addition, recurrent gliomas have an extremely poor prognosis, so innovative therapies are needed.
- Conditions
- Malignant Gliomas
- Being tested
- Cetuximab, Bevacizumab, Irinotecan
- Keywords
- Progressive primary Glioblastoma multiforme
- Medical subject headings
- Glioma
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
CetuximabDrug
BevacizumabDrug
IrinotecanDrug
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted20 Apr 2007 (estimated)
- Study startAug 2006
- Primary completionDec 2008
- Study completionDec 2008
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Malignant GliomasStudies of the same condition, open and under way.
- More trials run by Copenhagen University Hospital, RigshospitaletThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Non-randomised
- Intervention model
- Single group
- Masking
- None (open label)
- Enrolment
- 32 participants (actual)
Sponsor and investigators
- Lead sponsor
- Copenhagen University Hospital, Rigshospitalet
- Sponsor type
- University, hospital or other
- Collaborators
- Aalborg University Hospital, Odense University Hospital
- Investigators
- Ulrik Lassen, MD., PH.D., Principal investigator, Rigshospitalet, Dept. of Oncology
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT00463073
- Sponsor's protocol ID
- CBI-GBM-01
- Status last verified
- Dec 2008
- First submitted
- 19 Apr 2007
- Last updated
- 11 Dec 2008
- Results posted
- No
- Data monitoring committee
- No
Study at a glance
From the registry record, last updated by the sponsor on 11 Dec 2008. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- A Phase II Trial With Cetuximab, Bevacizumab and Irinotecan for Patients With Malignant Glioblastomas and Progression After Radiation Therapy and Temozolamide
- ClinicalTrials.gov ID
- NCT00463073
- Acronym / sponsor ID
- CBI-GBM-01
- Conditions
- Malignant Gliomas
- Keywords
- Progressive primary Glioblastoma multiforme
- Phase
- Phase 2
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 32 participants (actual)
- Lead sponsor
- Copenhagen University Hospital, RigshospitaletUniversity, hospital or other
- Collaborators
- Aalborg University Hospital, Odense University Hospital
- Study start
- Aug 2006
- Primary completion
- Dec 2008 (actual)
- Study completion
- Dec 2008 (actual)
- First posted
- 20 Apr 2007 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Irinotecan has demonstrated activity in malignant gliomas in multiple phase II studies. The activity is limited, with an approximately 15 % response rate and a progression-free survival of 3-5 months. Given the synergy between irinotecan and bevacizumab in colorectal cancer, and the high-level expression of vascular endothelial growth factor on malignant gliomas, one would expect synergy between bevacizumab and irinotecan against gliomas. In addition, 40-50 % of GBM have EGFR amplification/mutation making the EGFR an additional target. By combing cetuximab, with irinotecan and bevacizumab, one would expect further response, than irinotecan and bevacizumab alone. In addition, recurrent gliomas have an extremely poor prognosis, so innovative therapies are needed.
Study design
- Allocation
- Non-randomised
- Intervention model
- Single group
- Masking
- None (open label)
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (20 listed)
- Written informed consent
- Histological verification of primary GBM
- Recurrence or progression after standard treatment (debulking surgery of possible, radiotherapy and temozolamide within last six months)
- Evidence of measurable recurrent progressive primary GBM (CT/MRI scan)
- PS 0-2 (ECOG scale)
Key exclusion criteria (18 listed)
- Radiotherapy or chemotherapy within the last 4 weeks.
- Co-medication that may interfere with study results; e.g. immunosuppressive agents other than corticosteroids
- Prior EGFR- or VEGFR- based therapy.
- Any condition (medical, social, psychological), which would prevent adequate information and follow-up
- Any other active malignancy or previous malignancies within the last 5 years, except, adequately treated basal or squamous cell carcinoma of the skin, or carcinoma in situ.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Cetuximab | Drug | – |
| Bevacizumab | Drug | – |
| Irinotecan | Drug | – |
Primary outcome
Not reported in the source record.
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 11 Dec 2008.
Related trials for Malignant Gliomas
RecruitingPhase 1
A Phase 1 Safety and Dose Finding Study of GLIX1 in Adults With Recurrent or Progressive High-grade Glioma
Glioblastoma Multiforme of Brain, Glioma
RecruitingEarly Phase 1
Intratumoral Extracellular Metabolic Impact of DFMO and AMXT 1501 in Patients With Diffuse or High Grade Glioma
Diffuse Glioma, Malignant Glioma
Active, not recruitingPhase 1
Genetically Modified T-cells in Treating Patients With Recurrent or Refractory Malignant Glioma
Recurrent Glioblastoma, Recurrent Malignant Glioma
Active, not recruitingPhase 1/2
A Study of the Drug Selinexor With Radiation Therapy in Patients With Newly-Diagnosed Diffuse Intrinsic Pontine (DIPG) Glioma and High-Grade Glioma (HGG)
Malignant Glioma
RecruitingPhase 2
Entrectinib as a Single Agent in Upfront Therapy for Children <3 Years of Age With NTRK1/2/3 or ROS1-FUSED CNS Tumors
High Grade Glioma, CNS Tumor
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Ulrik Lassen, MD., PH.D. principal investigator
Rigshospitalet, Dept. of Oncology
3 sites in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 2 study testing Cetuximab, Bevacizumab and Irinotecan in people with Malignant Gliomas, run by Copenhagen University Hospital, Rigshospitalet at 3 sites in Denmark.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 20 inclusion and 18 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 11 Dec 2008. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 3 sites in Denmark. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 2 studies give the treatment to a larger group to see whether it has the intended effect and to keep checking safety.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 11 Dec 2008.